University of Arizona Sarver Heart Center and UA Division of Cardiology spinoff Avery Therapeutics Inc. has won another recognition—this one global—with the recent announcement that it will receive the “Technologies of Tomorrow” award as a BUZZ of BIO winner at the 2018 BIO International Convention in Boston in June.
The news was released actually in April by the Biotechnology Innovation Organization, which hosts the convention June 4-7 at the Boston Convention and Exhibition Center.
The story was picked up by the Arizona Bioindustry Association (AZBIO) and the Arizona Daily Star. Competition for the award is nationwide, but the event, now in its 25th year, attracts more than 16,000 attendees and 1,800 exhibitors from 70-plus countries.
In February, Avery was among six Arizona firms to receive 2018 Bioscience Entrepreneurship Program awards from the Flinn Foundation worth $30,000 each. Since 2014, the Phoenix-based foundation has allocated $825,000 in grants to nonprofits to administer funding and services to 28 bioscience startups.
Avery Therapeutics is a Tucson-based startup company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle. Its lead product, MyCardia, a tissue-engineered heart graft developed to treat heart failure, is in the pre-clinical development phase. MyCardia is positioned to be the world’s first off-the-shelf product for treating heart failure.
Avery was founded by Steve Goldman, MD, a professor of medicine in the UA Division of Cardiology and a Sarver Heart Center research scientist; Jordan Lancaster, PhD, an assistant research scientist at the Sarver Heart Center; and Jen Watson Koevary, PhD, Avery’s chief operating officer who earned her doctoral degree from UA Biomedical Engineering.
Both Tech Launch Arizona, the commercialization arm of the University of Arizona that helps bring innovations developed there to market, and the UA BIO5 Institute have provided assistance in the development of the company and its products.
“With UA Roots, Avery Therapeutics Selected for Flinn Bioscience Entrepreneurship Program” | Posted Feb. 22, 2018